Aktis Oncology (NASDAQ:AKTS – Get Free Report) was upgraded by investment analysts at Raymond James Financial to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.
Several other research firms also recently issued reports on AKTS. HC Wainwright upped their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Weiss Ratings downgraded shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, June 9th. Finally, William Blair assumed coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.
Check Out Our Latest Stock Analysis on AKTS
Aktis Oncology Stock Up 9.4%
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The company had revenue of $1.87 million for the quarter. On average, equities research analysts expect that Aktis Oncology will post -1.62 earnings per share for the current year.
Aktis Oncology Company Profile
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Featured Stories
- Five stocks we like better than Aktis Oncology
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
